Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

XORTX Therapeutics Inc > JUNKY RoadRunner Financiers took FULL advantage of Dr. CEO!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by SpaceLabson Nov 18, 2021 11:43am
69 Views
Post# 34141100

RE:RE:RE:RE:JUNKY RoadRunner Financiers took FULL advantage of Dr. CEO!

RE:RE:RE:RE:JUNKY RoadRunner Financiers took FULL advantage of Dr. CEO!CEO has TOO much on his plate as CEO and Doctor in control of Med Production going forward.
He needs a Break, let AB42 take on CEO's duties.

XRX has No Legs now, Cheap shares are going into CHEAP Hands also at the moment where it trades and Tax Loss has nothing to do in a mere 1000s shares traded daily by Manipulators.

Road Runners should get their Institutional Friends to start buying if they have ANY CONNECTIONS, NOPE ! none out there.



diamondlessnono wrote: Maybe the plan is to get everyone thats unhappy to sell? They didn't move to another exchange for nothing. We will most likely see it around 2.50 for a while. Why would they make a run, when it's tax time?


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities